Sudarshan Pharma Industries Ltd — Important, 08-09-2025: Company Update

Sudarshan Pharma has acquired an operational Active Pharmaceutical Ingredient (API) manufacturing facility in Telangana from Srigen Lifesciences for 25.50 Cr. This strategic investment significantly boosts SPIL's manufacturing capacity, accelerating its growth in high-demand API and specialty chemicals sectors. The acquisition enables immediate production scale-up, faster market entry, and an expanded portfolio of complex, high-margin molecules like Ropivacaine and Apixaban. This move strengthens SPIL's market position, enhancing its ability to serve global markets and is expected to contribute positively to future revenue and profitability, creating long-term shareholder value.